INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT FOR RADIATION RETINOPATHY

Abstract

Purpose: To assess the efficacy of a 0.18 mg intravitreal fluocinolone acetonide (FA) implant (Yutiq, EyePoint Pharmaceuticals, Watertown, MA) as a treatment option for patients with radiation retinopathy-related cystoid macular edema. Methods: A retrospective review of seven patients treated for uveal melanoma who developed radiation retinopathy-related cystoid macular edema. They were initially treated with intravitreal anti–vascular endothelial growth factor and/or steroid injections and then transitioned to intravitreal FA implant. Primary outcomes include best-corrected visual acuity, central subfield thickness, and number of additional injections. Results: After FA implant insertion, best-corrected visual acuity and central subfield thickness remained stable in all patients. The variance in best-corrected visual acuity decreased from 75.5 ETDRS letters (range 0–199 letters) to 29.8 (range 1.2–134) after FA implant insertion. Mean central subfield thickness was 384 µm (range 165–641) and 354 µm (range 282–493) before and after FA implant insertion, resulting in a 30-µm mean reduction. The number of intravitreal injections (average 4.9, range 2–10) decreased after intravitreal FA implant insertion with only two patients requiring one additional FA implant (average 0.29, range 0–1) over a mean of 12.1 months (range 0.9–18.5) follow-up. Conclusion: Intravitreal FA implant is an effective treatment for cystoid macular edema radiation retinopathy. The slow release of steroid allows for sustained control of macular edema, which correlated with stable visual acuity and decreased injection burden for patients.